You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
盤中異動 | 康希諾生物-B盤中上漲8%,報於171.8港元

2021年11月15日9時37分,康希諾生物-B(HK06185)盤中上漲8%,報於171.8港元,成交額達4996.81萬港元,換手率達到0.03%。

11月11日訊,11月11日康希諾生物-B(06185.HK)發佈公告,2021年11月11日,公司與浦發銀行訂立結構性存款協議VII,據此,公司同意於浦發銀行購買結構性存款本金金額人民幣7億元。

11月1日,瑞銀:維持康希諾生物-B(06185)“買入”評級,目標價降至361港元。10月5日,美銀證券:市場對抗新冠候選藥消息反應過度,維持康希諾生物-B(06185)“買入”評級。9月21日,西南證券:建議持續重點佈局醫藥核心資產和“醫保免疫”下“專精特新”細分龍頭。

最新的財務數據顯示,公司於2021年3季度,營業收入10.24億人民幣,淨利潤3.97億人民幣;營業收入同比增加62199.89%,毛利潤同比增加40543.04%,淨利潤同比增加638.42%。

盈立趨勢長盈模型最近一次交易信號,2021年11月5日出現觀望信號,觸發價格爲192.4港元(信號僅供參考)。

uSMART智能寫手的信息、數據均來自媒體公開報道,智能寫手不能保證其完全準確,內容僅供參考,不構成投資建議。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account